Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review.

ABSTRACT: Although corticosteroids are the standard first-line therapy for pulmonary sarcoidosis, long-term and high-dose use of these drugs are associated with increased risk of adverse events and high healthcare utilization costs. Treatment guidelines for pulmonary sarcoidosis indicate that off-label immunomodulators and biologics may be warranted for severe disease. Repository corticotropin injection (RCI, Acthar^® Gel), a complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides, is one of only two therapies approved by the US Food and Drug Administration for symptomatic pulmonary sarcoidosis and is recommended by current European Respiratory Society treatment guidelines for use on a case-by-case basis. With its unique anti-inflammatory and immunomodulatory me

SUBMITTER: Mirsaeidi M 

PROVIDER: S-EPMC8861221 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature